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Intra-individual variability in kidney function is a common
phenomenon; however, predictors of kidney function
variability and its prognostic significance are not known. To
examine this question, we assembled a cohort of 51,304 US
veterans with an estimated glomerular filtration rate (eGFR)
o60ml/min at the end of the study period and who had at
least two eGFR measurements during the previous 3 years.
Variability in kidney function was defined for each patient as
the coefficient of variation of the regression line fitted to all
outpatient measures of eGFR during this time frame. In
adjusted analyses, blacks, women, and those with Current
Procedural Terminology and ICD-9-CM diagnostic codes for
hypertension, diabetes, cardiovascular disease, peripheral
artery disease, chronic lung disease, hepatitis C, dementia,
acute kidney injury, and those with a greater number of
hospitalizations had greater variability in eGFR. After a
median follow-up of 4.9 years, there were 23.66%, 25.68%,
and 31.23% deaths among patients in the lowest,
intermediate, and highest tertiles of eGFR variability,
respectively. Compared with the referent (those in the lowest
tertile), patients in the highest tertile had a significantly
increased risk of death with a hazard ratio of 1.34 (1.28–1.40),
an association consistently present in all sensitivity analyses.
Thus, our results demonstrate that greater variability in
kidney function is independently associated with increased
risk of death.
Kidney International (2012) 82, 1208–1214; doi:10.1038/ki.2012.276;
published online 1 August 2012
KEYWORDS: acute kidney injury; chronic kidney disease; eGFR slope;
longitudinal data; mortality risk; variability
Dynamic fluctuations (or longitudinal intra-individual
variability) in clinical and laboratory parameters often
contribute additional prognostic information beyond that
provided by cross-sectional data. For example, patients with
greater intra-individual variability in body weight, hemoglo-
bin A1c, and hemoglobin are at a greater risk of death,
whereas those with greater variability in heart rate have a
lower risk of death.1–9
Variability in kidney function is a commonly observed
phenomenon in the outpatient clinical setting. Such
variability is likely a marker of both intrinsic renal disease
(e.g., renal microvascular disease, impaired autoregulatory
mechanisms, or limited renal functional reserve) and
extrinsic factors (e.g., changes in intravascular volume status,
congestive heart failure, liver disease, pulmonary disease,
or medications). Although prior studies have evaluated
the relationship between mortality and cross-sectional
measures of kidney function,10 and with rate of kidney
function change over time,11–15 to our knowledge the
predictors and prognostic significance of variability in kidney
function have not been evaluated. We hypothesized that
greater variability in kidney function would be associated
with increased risk of death.
RESULTS
Patients with greater estimated glomerular filtration rate
(eGFR) variability were slightly younger, were more likely to
be black and to be female, and had a higher prevalence of
diagnosed hypertension, diabetes mellitus, cardiovascular
disease, peripheral artery disease, cerebrovascular disease,
chronic lung disease, hepatitis C, dementia, and acute kidney
injury based on diagnostic codes. These patients also had a
greater number of hospitalizations during the 3-year period
before study entry (Table 1). These associations remained
statistically significant in adjusted analyses (P-value for trend
across tertiles o0.0001) (Table 2).
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Kidney function variability and the risk of death
During a median follow-up of 4.9 years, there were a total of
13,779 (26.86%) deaths among cohort members, including
4047 (23.66%) among patients in the lowest tertile of
variability (low variability), 4391 (25.68%) among those in
the second tertile of variability (intermediate variability), and
5341 (31.23%) among those in the highest tertile of
variability (high variability) (Figure 1). In an unadjusted












Median coefficient of variation *100 (min–max) 9.1 (0–100.6) 4.8 (0–7.1) 9.1 (7.1–11.4) 14.8 (11.4–100.6) o0.0001
Average age±s.d. 68.64±11.04 69.08±10.87 68.86±10.87 67.97±11.34 o0.0001
Race
White 42,879 (83.58%) 14,682 (85.85%) 14,408 (84.25%) 13,789 (80.63%) o0.0001
Black 7236 (14.10%) 2033 (11.89%) 2309 (13.50%) 2894 (16.92%) o0.0001
Other 1189 (2.32%) 387 (2.26%) 384 (2.25%) 418 (2.44%) 0.2650
Male gender 48,376 (94.29%) 16,320 (95.43%) 16,224 (94.87%) 15,832 (92.58%) o0.0001
Hypertension 41,772 (81.42%) 13,386 (78.27%) 14,024 (82.01%) 14,362 (83.98%) o0.0001
Diabetes mellitus 19,459 (37.93%) 5526 (32.31%) 6796 (39.74%) 7137 (41.73%) o0.0001
Cardiovascular disease 8137 (15.86%) 2088 (12.21%) 2716 (15.88%) 3333 (19.49%) o0.0001
Peripheral artery disease 1762 (3.43%) 426 (2.49%) 574 (3.36%) 762 (4.46%) o0.0001
Cerebrovascular disease 158 (0.31%) 37 (0.22%) 56 (0.33%) 65 (0.38%) 0.0066
Chronic lung disease 12,861 (25.07%) 3846 (22.49%) 4261 (24.92%) 4754 (27.80%) o0.0001
Hepatitis C 1915 (3.73%) 490 (2.87%) 566 (3.31%) 859 (5.02%) o0.0001
Dementia 3700 (7.21%) 1050 (6.14%) 1196 (6.99%) 1454 (8.50%) o0.0001
Hospitalization 14,178 (27.64%) 3095 (18.10%) 4485 (26.23%) 6598 (38.58%) o0.0001
Acute kidney injury 3275 (6.38%) 881 (5.15%) 1086 (6.35%) 1308 (7.65%) o0.0001
Serum albumin (g/dl) ±s.d. 3.0±2.2 3.0±1.6 3.0±1.7 3.0±2.8 0.0238
Average initial eGFR (ml/min)±s.d. 65.78±17.17 66.55±17.00 65.42±16.42 65.37±18.02 o0.0001
Average final eGFR (ml/min)±s.d. 46.86 ±10.27 47.85±9.77 46.99±10.15 45.75±10.75 o0.0001
Average rate of eGFR change/year±s.d.b 2.53±7.64 1.95±6.86 2.21±6.31 3.43±9.32 o0.0001
Median number of eGFR measurements
(25th–75th percentile)
5 (4–8) 4 (3–6) 6 (4–8) 6 (4–9) o0.0001
Median follow-up in years (25th–75th percentile)c 4.89 (4.41–4.97) 4.88 (4.50–4.97) 4.90 (4.51–4.97) 4.89 (4.07–4.97) o0.0001
Median time between index and last eGFR in years
(25th–75th percentile)d
2.20 (1.73–2.55) 2.06 (1.57–2.45) 2.28 (1.85–2.59) 2.25 (1.78–2.59) o0.0001
Abbreviation: eGFR, estimated glomerular filtration rate.
aTertiles of eGFR variability were defined using the coefficient of variation as the measure of variability for the primary analysis. Coefficient of variation is multiplied by 100 and
presented as a percentage.
% Represents the percentage within group (column percentage).
bReflects the rate of change of eGFR per year calculated using an Ordinary Least Squares (OLS) regression method fitted to all outpatient eGFR readings for each patient. The
slope of the regression line b describes the rate of change in kidney function (eGFR) over time.
cFollow-up time is the time between time zero (cohort entry on October 1, 2002) and censorship.
dDescribes the time between the index and the final eGFR during the 3 years preceding cohort entry (October 1, 1999 to September 30, 2002).

















Age (per year) 1.0 1.00 0.99–1.00 0.99 0.99–1.00 0.0807
Black versus White 1.0 1.02 0.98–1.07 1.13 1.08–1.17 o0.0001
Female versus Male 1.0 1.19 1.07–1.31 1.75 1.59–1.92 o0.0001
Hypertension 1.0 1.20 1.13–1.26 1.37 1.29–1.45 o0.0001
Diabetes mellitus 1.0 1.33 1.27–1.40 1.38 1.32–1.45 o0.0001
Cardiovascular disease 1.0 1.20 1.12–1.27 1.33 1.25–1.42 o0.0001
Peripheral artery disease 1.0 1.17 1.03–1.34 1.37 1.21–1.55 o0.0001
Hepatitis C 1.0 1.05 0.93–1.20 1.36 1.21–1.54 o0.0001
Dementia 1.0 1.08 0.99–1.17 1.20 1.10–1.3 0.0001
Serum albumin (per gram/dl) 1.0 1.01 0.99–1.02 1.01 0.99–1.02 0.3964
eGFR slope (per ml/min/year) 1.0 0.99 0.99–1.00 0.98 0.98–0.98 o0.0001
Hospitalizations 1.0 1.53 1.45–1.62 2.41 2.28–2.54 o0.0001
Acute kidney injury 1.0 1.19 0.94–1.52 2.44 1.97–3.02 o0.0001
Abbreviation: eGFR, estimated glomerular filtration rate.
aFully adjusted model for additional covariates including cerebrovascular disease, chronic lung disease, and number of eGFR measurements. All covariates in this model are
baseline covariates.
Bold values are statistically significant.
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Cox survival analysis, patients with high variability (hazard
ratio¼ 1.34, 95% CI¼ 1.28–1.40) had an increased risk of
death compared with the referent group (P for trend across
tertiles o0.001) (Table 3). In a number of models adjusted
for demographic characteristics, diagnosed comorbid condi-
tions including acute kidney injury, initial eGFR, eGFR slope,
number of eGFR measurements, and hospitalizations, the
association of eGFR variability with mortality remained
significant (hazard ratio¼ 1.34, 95% CI¼ 1.28–1.40), and
there was a significant trend of increased risk of death across
tertiles (P value for trend across tertiles o0.001). Results
were consistently similar in all sensitivity analyses (Table 3)
and in subgroup analyses based on eGFR category and eGFR
slope (Table 4).
DISCUSSION
In a large national cohort of US veterans, there were
systematic differences in the characteristics of patients
with greater versus lesser variability in eGFR. Even after
adjustment for these characteristics, greater variability
in kidney function was associated with an increased risk
of death. This association was independent of both
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Figure 1 |Kaplan–Meier survival curves of patients according
to low (blue line), intermediate (red line), and high (green
line) estimated glomerular filtration rate variability.























Unadjusted model 1.00 — 1.03 0.99–1.08 1.34 1.28–1.40 o0.0001
Adjusted for AKIa 1.00 — 1.03 0.99–1.08 1.32 1.26–1.38 o0.0001
Adjusted for AKIb 1.00 — 1.03 0.99–1.08 1.31 1.25–1.36 o0.0001
Adjusted for demographicsc 1.00 — 1.04 0.99–1.09 1.40 1.34–1.46 o0.0001
Adjusted for demographics,
laboratory parameters, and AKId
1.00 — 1.04 0.99–1.09 1.38 1.32–1.44 o0.0001




1.00 — 1.05 1.01–1.10 1.34 1.28–1.40 o0.0001
Sensitivity analysesg
Residual s.d. 1.00 — 1.00 0.96–1.04 1.12 1.08–1.17 o0.0001
Root mean square error 1.00 — 0.99 0.95–1.03 1.27 1.21–1.32 o0.0001
eGFR based on MDRD 1.00 — 1.15 1.12–1.23 1.35 1.23–1.54 o0.001
Inverse serum creatinine 1.00 — 1.11 1.06–1.16 1.46 1.40–1.52 o0.0001
Outpatient and inpatient eGFRs 1.00 — 1.07 1.03–1.12 1.39 1.33–1.45 o0.0001
Adjusted for use of ACE
inhibitors, ARBs, diuretics,
NSAIDs, and beta blockersh
1.00 — 1.05 1.01–1.10 1.34 1.28–1.40 o0.0001
Abbreviations: ACE, angiotensin-converting enzyme; AKI, acute kidney injury; ARBs, angiotensin receptor blockers; eGFR, estimated glomerular filtration rate; MDRD,
Modification of Diet in Renal Disease; NSAIDs, nonsteroidal anti-inflammatory drugs.
aAKI before cohort entry (during the exposure window from 1 October 1999 to 30 September 2002).
bAKI as time-varying covariate during follow-up (1 October 2002 till censorship or death). AKI was defined as an increase of 50% or more in serum creatinine during a
hospitalization of any cause where baseline serum creatinine defined as the lowest value between 90 days before hospital admission date.
cDemographic characteristics include age, race, and gender.
dLaboratory parameters include eGFR, eGFR slope, number of eGFR measurements, and serum albumin.
eHospitalization was defined as any hospitalization during the 3 years preceding cohort entry (between 1 October 1999 and 30 September 2002).
fClinical comorbid conditions include hypertension, diabetes mellitus, cardiovascular disease, peripheral artery disease, chronic lung disease, hepatitis C, cerebrovascular
disease, and dementia. In the Cox models, these covariates were treated as time-dependent covariates from time zero onward (1 October 2002 until death or censorship).
gSensitivity analyses: (1) using alternative measures of variability (residual s.d. and root mean square error), (2) using the MDRD study equation to estimate eGFR, (3) using
variability of serum creatinine (coefficient of variation of the slope of inverse serum creatinine (1/serum creatinine) vs. time), (4) using inpatient and outpatient eGFR measures
to calculate eGFR slope and eGFR variability, and (5) adjusting for medication use.
hMedication use was defined as any use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, nonsteroidal anti-inflammatory drugs, and beta
blockers in the 3 years preceding cohort entry. All models in sensitivity analyses are fully adjusted for demographic characteristics, laboratory parameters, AKI,
hospitalizations, and clinical comorbid conditions.
Bold values are statistically significant.
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regardless of the method used to estimate kidney function or
variability.
We speculate that differences in intra-individual variability
in outpatient eGFR measures likely reflect both differences in
the ability to maintain renal homeostasis (i.e., to maintain
stable renal function in response to exposures that may
compromise that function) and unmeasured differences in
the frequency and nature of exposures that may threaten such
homeostasis. The ability to maintain renal homeostasis may
depend not only on intrinsic renal factors but also on the
function of organ systems other than the kidney. Consistent
with this possibility, patients with other comorbid conditions
were more likely to have greater variability in kidney
function. However, even after adjustment for these other
conditions, greater variability in outpatient eGFR contrib-
uted additional prognostic information. As variability in
eGFR likely reflects both factors intrinsic and extrinsic to the
kidney, higher mortality in patients with greater variability in
eGFR probably reflects unmeasured exposures that are not
easily captured in analyses of this sort and may also be
difficult to quantify in the clinical setting (e.g., volume status,
presence and severity of intercurrent illness), as well as more
global differences in resilience not captured by measured
comorbid conditions.
In the clinical setting, transient changes in serum
creatinine are common. A sudden rise in serum creatinine
(or loss of eGFR) often triggers interventions directed at the
suspected underlying cause (e.g., discontinuation of a diuretic
or angiotensin-converting enzyme inhibitor). A subsequent
return in serum creatinine to the patient’s prior baseline level
usually provides reassurance that the intervention was
appropriate. Our findings suggest that patients in whom such
fluctuations are more common are nevertheless at increased
risk for death, despite a return of serum creatinine to baseline.
When viewed over time, such variability provides additional
prognostic information beyond baseline eGFR10 and chronic
eGFR slope,11–14 both of which are known to be associated
with an increased risk of death. In other words, even in
patients who do not experience progressive loss of eGFR over
time, greater variability in eGFR identifies those patients at
increased risk of mortality. Although greater variability in
eGFR in this context most likely reflects confounding by
unmeasured factors, it is precisely for this reason that greater
variability in eGFR may be clinically useful: many of the
factors that account for differences in variability (and
mortality) between individuals may be much harder to
quantify. eGFR variability may be difficult to compute;
however, similar to the automation of eGFR reporting that
is now part of numerous electronic health records software,
longitudinal measures of kidney function (eGFR slope and
eGFR variability) may also be automated.16
This study has the following limitations. The cohort
included mostly white men, and thus the results may not be
generalizable to less narrowly defined populations. The
imperfect nature of administrative data and the retrospective
design of the study may also lead to sampling bias























Tertiles of eGFR variability and the risk of death according to eGFR slope
eGFR slope 40ml/min/year
(n=15,850)
1.00 — 0.97 0.89–1.04 1.21 1.12–1.31 o0.0001
eGFR slope 0 to 1ml/min/year
(n=5,451)
1.00 — 0.92 0.80–1.06 1.19 1.03–1.36 o0.0001
eGFR slope –1 to 4ml/min/year
(n=12,192)
1.00 — 1.14 1.04–1.25 1.33 1.22–1.46 o0.0001
eGFR slope o4ml/min/year
(n=17,811)
1.00 — 1.10 1.02–1.18 1.42 1.32–1.52 o0.0001
Tertiles of eGFR variability and the risk of death according to eGFR slope in descending tertiles
eGFR slope tertile 1 (n=17,102) 1.00 — 0.96 0.89–1.04 1.22 1.13–1.31 o0.0001
eGFR slope tertile 2 (n=17,101) 1.00 — 1.08 1.00–1.16 1.32 1.23–1.43 o0.0001
eGFR slope tertile 3 (n=17,101) 1.00 — 1.10 1.02–1.18 1.40 1.31–1.51 o0.0001
eGFR slope tertiles are in descending order
Tertiles of eGFR variability and the risk of death according to eGFR
eGFR between 60 and 45ml/min
(n=32,855)
1.00 — 1.09 1.03–1.16 1.35 1.27–1.43 o0.0001
oeGFR between 45 and 30ml/min
(n=14,102)
1.00 — 1.03 0.96–1.11 1.34 1.25–1.44 o0.0001
eGFR o30ml/min (n=4,347) 1.00 — 0.97 0.87–1.08 1.15 1.04–1.28 o0.0001
Abbreviation: eGFR, estimated glomerular filtration rate.
aFully adjusted models for demographic, laboratory, and clinical comorbid conditions.
Bold values are statistically significant.
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and inaccurate measurements of the predictor variables.
To minimize such measurement bias, we used published
definitions of comorbid illnesses that are validated for use
in administrative data (Supplementary Appendix Table S1
online). Because of inclusion criteria specifying the minimum
number of creatinine measurements required to fulfill our
inclusion criteria, and as the frequency of creatinine mea-
surements is probably a surrogate marker of poorer overall
health, we may have systematically missed those who rarely
seek care within the Veterans Affairs (VA), and our cohort
may be sicker than a broader population of veterans.
In conclusion, in a large national cohort of US veterans,
greater variability in kidney function was associated with an
increased risk of death that was independent of baseline
eGFR, eGFR slope, and measured patient characteristics
associated with greater variability.
MATERIALS AND METHODS
Patients
Using administrative data from the United States Department of
Veterans Affairs, we identified users of the VA health-care system
who were alive on 1 October 2002 (n¼ 457,493) and had at least
three outpatient serum creatinine measurements recorded in
national VA data sources over the preceding 3 years (between 1
October 1999 and 30 September 2002) (n¼ 214,608). Patients were
excluded if their eGFR before cohort entry (the eGFR most
proximate to time zero) was greater than 60ml/min (n¼ 162,436)
or if they had received a kidney transplant or had undergone at least
one episode of dialysis before cohort entry on 1 October 2002
(n¼ 865), yielding an analytic cohort of 51,304 patients. The study
was approved by the Institutional Review Board at the Saint Louis
Veterans Affairs Medical Center, Saint Louis, MO.
Data sources
The VA operates one of the largest integrated health-care systems
under a single management structure in the world, and maintains
large centralized data repositories that provide a unique opportunity
to examine longitudinal behavior of chronic diseases and long-term
outcomes.17–20 We used the inpatient and outpatient medical SAS
data sets (SAS Institute, Cary, NC) (which include utilization data
related to all inpatient and outpatient encounters within the VA
system) to ascertain detailed patient demographic characteristics
and comorbidity information based on Current Procedural
Terminology codes, and ICD-9–CM diagnostic and procedure codes
associated with inpatient and outpatient encounters.21,22 The VA
Decision Support System Laboratory Results file (a comprehensive
database that includes VA-wide results for selected laboratory tests
obtained in the clinical setting) provided information on outpatient
and inpatient serum creatinine measurements during the 3-year
period preceding cohort entry.23 The VA Vital Status file provided
death follow-up through 30 September 2008. Prescription drug
information for cohort members was obtained from the Pharmacy
Benefits Management system.24
Primary predictor variable
The primary predictor variable for all analyses was variability in
eGFR. Variability was defined as the coefficient of variation of the
regression line coefficient (b) that is fitted to all outpatient eGFR
measures for each patient. We used the coefficient of variation as the
variability measure in the primary analysis, because it is normalized to
the mean value for each patient and thus it is dimensionless and could
be easily compared across patients with different levels of eGFR.1,2,4,7
We examined alternative measures of variability in sensitivity
analyses. eGFR was calculated using the CKD-EPI equation.25 When
race data were missing (o1% of patients), we assumed that patients
were non-black. For each patient, we calculated eGFR slope and eGFR
variability (coefficient of variation) by fitting an ordinary least square
regression line to all outpatient eGFR measures from 1 October 1999
through 30 September 2002.11–14,26
Outcome
The primary outcome was time from cohort entry (1 October 2002)
to death. Death data were ascertained through 30 September 2008.
Covariates
Baseline covariates were ascertained at the time of cohort entry and
for the preceding 3-year period. Covariates included acute kidney
injury, initial eGFR, eGFR slope, serum albumin, number of eGFR
measurements, age, race, gender, and diabetes mellitus, hypertension,
cardiovascular disease, peripheral artery disease, cerebrovascular
disease, chronic lung disease, hepatitis C, dementia, and number of
hospitalizations. acute kidney injury was defined as an increase of
50% or more in serum creatinine during a hospitalization of any
cause where baseline serum creatinine was defined as the lowest value
between 90 days before hospital admission date.15,27 Race/ethnicity
was categorized as white, black, or other (Latino, Asian, Native
American, other racial/ethnic minority groups, or unknown).
Comorbidities were assigned on the basis of relevant ICD-9–CM
diagnostic and procedures codes and Current Procedural Terminol-
ogy codes in the VA Medical SAS data sets. Hospitalization was
defined as any inpatient hospital stay. These covariates were treated
as time-dependant covariates in survival analyses (from time zero on
1 October 2002 until censorship or death). The operational
definitions of all covariates are provided in Supplementary Appendix
Table S1 online.11,28–52
Statistical analysis
Differences in mean values for continuous variables were tested
using one-way analysis of variance. Differences in proportions for
categorical variables were tested using Pearson’s w2 test. Predictors of
increased variability were examined using an ordered logistic
regression model. In this model, baseline characteristics were used
to define the covariates. In all analyses, variability was categorized by
tertile, with the lowest tertile representing those patients with the
lowest variability (referent), the middle tertile representing those
with the intermediate variability, and the highest tertile representing
those with the greatest variability.
To determine whether eGFR variability is associated with all-
cause mortality, we used Cox regression models to estimate the
hazard ratio for the second and third tertiles of variability compared
with the lowest tertile after adjusting for other covariates. Additional
analyses were undertaken to evaluate the association in subgroups
based on eGFR category and eGFR slope. A P-value of 0.05 or less
was considered statistically significant. All analyses were performed
using SAS software version 6.12.
Sensitivity analyses
To evaluate the robustness of study results, we conducted the
following sensitivity analyses: (1) we used two alternative measures
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of variability, residual standard deviation and root mean square
error;2 (2) we used the abbreviated 4-variable Modification of Diet
in Renal Disease study equation based on age, gender, race, and
serum creatinine level as an alternative method to estimate
eGFR;53–55 (3) we measured variability in the coefficient of variation
of the slope of inverse serum creatinine (1/serum creatinine) versus
time; (4) we used inpatient and outpatient (rather than just
outpatient) eGFR measurements to calculate eGFR slope and eGFR
variability; and (5) we adjusted for medication use (including the use
of angiotensin-converting enzyme inhibitors, angiotensin receptor
blockers, diuretics, nonsteroidal anti-inflammatory drugs, and beta
blockers).
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